COVID-19 — Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)
Citation(s)
Efficacy and Safety of a Recombinant Neutralizing Human Anti-SARS-CoV-2 Monoclonal Antibody JS016 in Chinese Hospitalized Patients With SARS-CoV-2 Infection (COVID-19): a Multicenter, Randomized, Open-label, Controlled Trial